Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Lundbeck reports phase IIa results with Lu-AG06466 in Tourette's syndrome

March 30, 2020

Lundbeck discontinues foliglurax program in Parkinson's following phase IIa results

March 30, 2020

TET1 gene therapy patented by the Military Medical Institute Academy

March 30, 2020

Nobelpharma obtains approval in Japan for Melatobel

March 27, 2020

Roche presents gamma-secretase inhibitors

March 27, 2020

FDA approves Zeposia as oral treatment for relapsing forms of multiple sclerosis

March 27, 2020

Scorpion venom could be useful in fetal alcohol spectrum disorders

March 26, 2020

Chengdu Kanghong Pharmaceutical patents new analgesics

March 26, 2020

Japan first in world to approve Viltepso for Duchenne muscular dystrophy

March 26, 2020

Latuda tablets approved in Japan

March 26, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...